Raynaud's Phenomenon
Clinical Snapshot
Raynaud's phenomenon is episodic vasospasm of the small arteries and arterioles supplying the fingers — and, less often, the toes, ears, nose, and nipples — triggered by cold exposure or emotional stress and producing a characteristic sequence of colour change: white, then blue, then red.[1] It is genuinely common, with population estimates for primary Raynaud's phenomenon in the range of 3-5% of adults, a strong female predominance, and a materially higher prevalence in colder climates — making this a genuinely Canadian-winter-relevant condition a community pharmacist will see regularly, not an imported curiosity.[1][2]
The single most important framing point in this chapter is the distinction between primary and secondary Raynaud's phenomenon. Primary Raynaud's phenomenon — sometimes still called Raynaud's disease — is a functional vasospastic disorder with no identifiable underlying cause, typically begins in the teens or twenties, follows a symmetric and comparatively mild pattern, and carries an essentially benign long-term course with no tissue damage.[3][1] Secondary Raynaud's phenomenon reflects an identifiable underlying disease process — most importantly connective tissue disease, and above all systemic sclerosis (scleroderma), in which Raynaud's phenomenon is the presenting symptom in the great majority of patients and can precede the disease's other manifestations by years — and carries a genuine, non-theoretical risk of digital ulceration, critical digital ischemia, and tissue loss that primary disease essentially never does.[1][4]
This chapter covers the primary-versus-secondary distinction and the bedside and laboratory features that separate them, the classic tricolour sequence and its triggers, a genuine centrepiece drug-induced and drug-worsened Raynaud's phenomenon table — beta-blockers, ergot alkaloids and triptans, specific chemotherapy agents, clonidine, decongestants, ADHD stimulants, and interferons are all real, common, and frequently overlooked contributors a pharmacist is uniquely well positioned to catch on medication review — non-pharmacologic measures as genuine first-line treatment, dihydropyridine calcium channel blockers as first-line pharmacotherapy, and the escalation ladder (phosphodiesterase-5 inhibitors, topical nitrates, and, for severe or ulcerating secondary disease, intravenous prostanoids and surgical sympathectomy) reserved for disease that does not respond to first-line measures.
Recognize the Condition
The classic tricolour sequence
A textbook Raynaud's attack passes through three phases, each with its own distinct mechanism.[1]
- White (pallor) — an abrupt, well-demarcated vasospasm of the digital arteries and cutaneous arterioles cuts off blood flow almost completely, producing a sharply demarcated white or waxy digit, often with numbness or a "dead finger" sensation.
- Blue (cyanosis) — as the vasospastic phase continues, the small amount of blood still present in the capillaries and venules desaturates, producing a dusky blue-purple colour, frequently accompanied by aching or throbbing discomfort.
- Red (reperfusion/rubor) — once the vasospasm resolves, a brisk reactive hyperemia floods the digit with blood, producing a bright red colour, often with throbbing pain, tingling, or a burning sensation as sensation and circulation return.
Not every attack — and not every patient — passes through all three phases in a clean sequence; a biphasic pattern (white-then-blue, or white-then-red) or even a monophasic pallor-only attack is still entirely consistent with Raynaud's phenomenon.[1][2] Insisting on a textbook-perfect triphasic history before accepting the diagnosis is a common and avoidable error (see Common Errors to Avoid). What is genuinely required for the diagnosis is a well-demarcated colour change of the digit(s) — not simply "cold hands" or diffuse mottling.[2]
Triggers and distribution
Cold exposure is the classic trigger — and not only obvious cold, but comparatively subtle everyday exposures a patient may not connect to the diagnosis: reaching into a freezer or refrigerated grocery aisle, holding a cold drink, air conditioning, or a drop in ambient temperature well short of what most people would call "cold." Emotional stress is an independent trigger through the same sympathetically mediated vasospastic pathway, and the two commonly compound each other.[1] Attacks most often affect the fingers, typically sparing the thumb, and are frequently symmetric in primary disease; the toes, ears, nose, and nipples can also be affected, and Raynaud's phenomenon of the nipple is a real, under-recognized cause of pain during breastfeeding (see Special Populations).[1]
Primary versus secondary Raynaud's phenomenon — the central diagnostic distinction
Two genuinely different diagnoses behind the same colour change
Primary Raynaud's phenomenon
No identifiable underlying cause. Onset typically in the teens to twenties; women affected roughly 3-4 times more often than men; attacks are usually symmetric, comparatively mild to moderate, and improve with simple protective measures; there is no digital ulceration, pitting, or tissue loss; nailfold capillaries are normal; antinuclear antibody (ANA) testing is negative; a family history of Raynaud's phenomenon is common. The long-term course is genuinely benign.[3][1]
Secondary Raynaud's phenomenon
An identifiable underlying disease process is driving the vasospasm — most importantly connective tissue disease (systemic sclerosis foremost, but also systemic lupus erythematosus, Sjögren syndrome, dermatomyositis/polymyositis, mixed connective tissue disease, and rheumatoid arthritis), though a real minority of cases are non-autoimmune (see below). Onset is typically later (after age 30), attacks can be asymmetric or affect a single digit, and — critically — digital pitting, ulceration, or frank gangrene can occur. Nailfold capillaries are frequently abnormal (the "scleroderma pattern" — capillary dropout, giant/dilated capillaries, and microhemorrhages), and ANA or a specific autoantibody (anti-centromere, anti-topoisomerase I/anti-Scl-70, anti-RNA polymerase III) is frequently positive.[3][2][4]
Diagnostic classification criteria
Two complementary, widely used frameworks anchor the primary-versus-secondary distinction in practice. The original LeRoy and Medsger criteria define primary Raynaud's phenomenon by the presence of symmetric attacks, no evidence of peripheral vascular disease, no digital pitting/ulceration/gangrene, a normal nailfold capillaroscopy, a negative ANA, and a normal erythrocyte sedimentation rate — correctly classifying roughly 89% of patients at initial evaluation in the original validation cohort.[3] A subsequent international Delphi consensus (Maverakis et al.) refined the core diagnostic criteria to two required elements — patient-reported cold- or emotional-stress-triggered acral colour change, together with a biphasic colour response (pallor and/or cyanosis, plus erythema during recovery) — while retaining the same underlying primary-versus-secondary framework for the subsequent workup.[2]
Secondary causes beyond connective tissue disease
Not every case of secondary Raynaud's phenomenon is autoimmune. Consider and screen for: occupational vibration exposure (hand-arm vibration syndrome, from power tools — a real, compensable occupational condition worth asking about directly); thoracic outlet syndrome or another proximal arterial compression/embolic source, particularly with strictly unilateral symptoms; atherosclerotic peripheral arterial disease in an older patient with vascular risk factors; thromboangiitis obliterans (Buerger disease) in a younger patient who smokes; hypothyroidism; paraproteinemia or cryoglobulinemia; and drug-induced or drug-worsened Raynaud's phenomenon — a genuinely common and frequently overlooked cause covered as this chapter's centrepiece (see Drug Tables and Choose Initial Treatment).[1][5]
Differential diagnosis at a glance
| Consider | Distinguishing feature |
|---|---|
| Acrocyanosis | Persistent (not episodic) blue-violet discoloration of the hands/feet, painless, not relieved by warming in the same abrupt way, no true pallor phase |
| Erythromelalgia | The pathophysiologic opposite of Raynaud's phenomenon — episodic vasodilation with red, hot, burning extremities typically worsened by warmth and relieved by cooling |
| Chilblains (pernio) | Itchy, painful erythematous-to-violaceous papules/plaques from repetitive non-freezing cold/damp exposure; no true colour-phase sequence |
| Frostbite | Actual tissue freezing from a discrete cold exposure, not an episodic, repeated vasospastic pattern — see the separate Frostbite chapter |
| Peripheral arterial disease / atherosclerosis | Fixed, not episodic, reduced perfusion; diminished or absent pulses; claudication; risk-factor profile |
| Carpal tunnel syndrome | Paresthesia in a median-nerve distribution, typically nocturnal, without a true colour-change sequence |
| Complex regional pain syndrome | Follows a discrete inciting injury; pain, swelling, and trophic changes are typically more prominent and persistent than episodic colour change |
Risk Factors
- Female sex — primary Raynaud's phenomenon is roughly 3-4 times more common in women.[1]
- Family history of Raynaud's phenomenon.
- Younger age (primary disease) — typical onset in the teens to twenties.[3]
- Residence in, or regular exposure to, a cold climate — genuinely relevant to Canadian practice.[1]
- Tobacco use — nicotine is directly vasoconstrictive and both triggers and worsens attacks.
- Migraine history — both conditions share an underlying vasospastic tendency.
- Any connective tissue disease, especially systemic sclerosis, systemic lupus erythematosus, Sjögren syndrome, dermatomyositis/polymyositis, mixed connective tissue disease, or rheumatoid arthritis.[4]
- Occupational exposure to vibrating tools (hand-arm vibration syndrome).
- Hypothyroidism.
- Atherosclerotic vascular disease and its usual risk factors, in an older patient presenting with new symptoms.
- Any medication from the drug-culprit table — beta-blockers, ergot alkaloids/triptans, specific chemotherapy agents, clonidine, decongestants, ADHD stimulants, and interferons chief among them (see Drug Tables).[5]
- Repeated local cold injury, including a prior frostbite injury to the same digit.
Red Flags & Refer
Most Raynaud's phenomenon is primary and benign — but any of the following should prompt evaluation for secondary disease and, where indicated, urgent referral:
- Onset after age 30, particularly with no family history.
- Asymmetric attacks, or attacks confined to a single digit.
- Digital pitting, ulceration, or any sign of tissue breakdown.
- Puffy or sclerodactylous ("tight, shiny") fingers, or new skin thickening.
- Telangiectasias, especially on the face or hands.
- Abnormal nailfold capillaries on capillaroscopy (see Assessment & Diagnosis).
- A positive ANA or a specific autoantibody (anti-centromere, anti-topoisomerase I, anti-RNA polymerase III, or another connective-tissue-disease-associated antibody).
- Associated symptoms suggesting connective tissue disease — joint pain/swelling, dysphagia, new or worsening heartburn, dry eyes/mouth, proximal muscle weakness, unexplained weight loss, or unexplained dyspnea.
- Fixed, persistent pallor or cyanosis of a digit that is not relieved by warming, with severe pain, a non-healing ulcer, or any sign of gangrene — this is critical digital ischemia and warrants urgent same-day referral to rheumatology and/or vascular surgery, not routine follow-up (see Treatment Failure/Next Step and the Clinical Decision Algorithm).
- Strictly unilateral symptoms, especially with a positional component — screen for thoracic outlet syndrome or a proximal arterial/embolic source rather than assuming typical bilateral Raynaud's phenomenon.
- Pediatric onset with a positive ANA, a connective-tissue-disease-associated autoantibody, or abnormal nailfold capillaries — refer to pediatric rheumatology (see Special Populations).[6]
- A clear temporal relationship between new or worsening symptoms and a new or dose-increased medication from the drug-culprit table — reassess the medication with the prescriber rather than assuming it must be primary disease (see Drug Tables).[5]
Assessment & Diagnosis
History
Characterize the attack itself: distribution (symmetric versus asymmetric or single-digit), age of first attack, frequency, duration, and whether the classic colour sequence — or a biphasic/monophasic variant — is present.[2] Ask specifically about digital ulceration, pitting, or any wound that has not healed normally. Screen for connective-tissue-disease features: joint pain or swelling, skin tightening or thickening, dysphagia or new reflux, dry eyes or mouth, proximal muscle weakness, and unexplained weight loss. Take a complete medication history, including over-the-counter products (decongestants) and any recent dose change, and correlate the timeline of any new symptom against the medication list rather than treating this as a separate, later step — this is exactly where a pharmacist's structured medication review adds real diagnostic value.[5] Ask about occupational vibration exposure, smoking, and family history of Raynaud's phenomenon or connective tissue disease.
Examination
Examine the digits for pitting scars, active ulceration, sclerodactyly, digital swelling ("puffy fingers"), calcinosis, and telangiectasia. Check peripheral pulses and consider an Allen test if a proximal arterial or embolic cause is suspected. A single-digit or strictly unilateral presentation should prompt a more focused vascular examination, including for signs of thoracic outlet syndrome.
Nailfold capillaroscopy
A simple, non-invasive, in-office technique — a drop of oil is placed at the nailfold and the capillary bed is examined under magnification (a dermatoscope is often sufficient; a dedicated capillaroscope offers more detail) — that is genuinely useful for separating primary from secondary disease. Normal, regularly spaced capillary loops support primary disease; the "scleroderma pattern" — capillary dropout (avascular areas), enlarged or giant capillaries, and microhemorrhages — strongly suggests secondary disease, particularly systemic sclerosis, and should prompt rheumatology referral even before autoantibody results return.[7][2]
Laboratory investigations
For any patient with a red flag (see Red Flags & Refer): ANA, with reflex to an extended autoantibody panel (anti-centromere, anti-topoisomerase I/anti-Scl-70, anti-RNA polymerase III, and other connective-tissue-disease-associated antibodies as clinically indicated) if positive; complete blood count and inflammatory markers (ESR/CRP); and thyroid-stimulating hormone. Consider serum protein electrophoresis and cryoglobulins if paraproteinemia or a cryoglobulinemic process is suspected. A patient with a normal examination, normal nailfold capillaries, and no red flags does not require this full panel — over-investigating straightforward primary disease is its own avoidable error.
Applying the classification criteria
Apply the LeRoy-Medsger and international consensus criteria (see Recognize the Condition) systematically rather than relying on gestalt — a patient meeting every primary-disease criterion (symmetric attacks, no ulceration, normal capillaries, negative ANA, normal ESR) can be reassured and managed as primary disease; any single secondary-disease feature should prompt the fuller workup above and, where confirmed or strongly suspected, rheumatology referral.[3][2]
Differential diagnosis
See Recognize the Condition for the full comparison table (acrocyanosis, erythromelalgia, chilblains, frostbite, peripheral arterial disease, carpal tunnel syndrome, and complex regional pain syndrome as the principal alternatives to actively distinguish).
Treatment Targets
- Correctly classify primary versus secondary Raynaud's phenomenon before committing to a treatment intensity, since the two carry genuinely different urgency and risk.
- Reduce attack frequency, severity, and duration to a level the patient finds tolerable and that preserves function.
- Prevent digital ulceration and critical ischemia in secondary disease — this is the goal that actually matters clinically, not simply "fewer colour changes."
- Identify and address every modifiable drug-induced or drug-worsening contributor through a structured medication review, in collaboration with the prescriber.
- Support smoking cessation specifically because of its direct vasoconstrictive relevance, not as generic health advice.
- Exhaust non-pharmacologic measures before, and alongside, any pharmacotherapy for mild-to-moderate primary disease.
- Use the lowest effective calcium channel blocker dose, titrating to symptom control and tolerability rather than a fixed target dose.
- Escalate promptly — not after a prolonged trial-and-error period — once digital ulceration or critical ischemia is present.
- Refer secondary disease, and any red flag, for rheumatologic and/or vascular assessment rather than managing it indefinitely in isolation.
Choose Initial Treatment
Classify first, then treat — non-pharmacologic measures and a medication review come before any drug started specifically for Raynaud's phenomenon
Every patient, first visit confirm primary versus secondary status using the history, examination, and — for anyone with a red flag — nailfold capillaroscopy and autoantibody testing (see Assessment & Diagnosis). In parallel screen the full medication list against the drug-culprit table and discuss any modifiable culprit with the prescriber before assuming the presentation is idiopathic primary disease.[5][1]
Step 1 — Non-pharmacologic measures, for every patient
Preferred approach implement the full set of measures in Non-Pharmacologic Treatment — whole-body and local warming, layered clothing, smoking cessation, and trigger avoidance — as first-line management for every patient, including one ultimately started on a calcium channel blocker. For mild, infrequent primary disease, non-pharmacologic measures alone are often genuinely sufficient and no drug is needed.[1]
Step 2 — Structured medication review
Preferred approach systematically check every medication against the drug-culprit table (see Drug Tables). Situational where a flagged drug is genuinely needed for its primary indication (a beta-blocker after myocardial infarction, an ADHD stimulant with a clear functional benefit), discuss a dose reduction, a within-class substitution to a lower-risk agent, or — only in collaboration with the prescriber — a taper and discontinuation, rather than a pharmacist or patient stopping it unilaterally.[5]
Step 3 — Calcium channel blocker, when symptoms remain significant
1st-line pharmacotherapy a dihydropyridine calcium channel blocker — oral nifedipine, extended-release, is the best-studied agent — should be used first-line once non-pharmacologic measures and medication optimization leave symptoms frequent, severe, or functionally limiting, and is appropriate first-line pharmacotherapy for secondary as well as primary disease.[8] Start at a low dose and titrate upward against symptom control and tolerability (hypotension, headache, peripheral edema, reflex tachycardia); use the extended-release formulation rather than a short-acting one, which carries a materially higher risk of reflex tachycardia and hypotension without a corresponding efficacy benefit (see Common Errors to Avoid). Alternative felodipine or amlodipine (the latter available in this catalogue only as a fixed-dose combination product) are reasonable alternative dihydropyridines if nifedipine is not tolerated.[8]
Step 4 — Escalation for inadequate response or secondary disease
Escalate once a calcium channel blocker at the maximum tolerated dose does not adequately control symptoms — or immediately, in parallel with the calcium channel blocker, for secondary disease with digital ulceration or a high-risk connective-tissue-disease pattern — add a phosphodiesterase-5 (PDE5) inhibitor (sildenafil or tadalafil) and/or a topical nitrate; losartan or fluoxetine are reasonable alternative or adjunct agents with their own supporting trial evidence.[8][9]
Step 5 — Severe, refractory, or ulcerating secondary disease
Specialist-directed for digital ulceration or critical digital ischemia that does not respond to maximized combination oral therapy, intravenous prostanoid therapy (iloprost) is the guideline-endorsed escalation, administered at a specialized centre; botulinum toxin injection into the digital neurovascular bundles is a reasonable adjunct or alternative in refractory cases; and surgical digital sympathectomy is reserved for critical ischemia refractory to maximal medical therapy.[8] This tier of care needs rheumatology and/or vascular surgery co-management — see Red Flags & Refer and the Clinical Decision Algorithm.
Non-Pharmacologic Treatment
Warming — whole-body, not just local
Layered clothing and mittens (rather than gloves — keeping the fingers together conserves heat more effectively than separating them) are the mainstay, but the single most under-taught point is that core body warmth matters as much as local hand warmth: a cold torso itself triggers reflex peripheral vasoconstriction, so a well-insulated hat, scarf, and coat genuinely help protect the fingers, not only warm mittens on their own.[1] Chemical or battery hand and foot warmers are a simple, effective adjunct for outdoor exposure. At the first sign of an attack, warm water immersion of the affected digit(s) — not hot water, which risks a thermal injury to a digit with reduced sensation during the attack — will usually abort it.
Avoiding predictable triggers
- Abrupt cold exposure with no warning — reaching into a freezer or refrigerated grocery case, air conditioning set aggressively cold, or handling a cold drink — is a genuinely common and underappreciated trigger; anticipate and protect against it, not only obvious outdoor cold.
- Emotional stress — where feasible, stress-reduction techniques and biofeedback have modest supporting evidence and are a reasonable adjunct for a motivated patient.
- Occupational vibrating tools — workplace modification (anti-vibration gloves, tool substitution, scheduled breaks) where hand-arm vibration syndrome is a contributing factor.
- Caffeine — evidence is weaker and mixed, but a trial of reduced intake is reasonable and low-risk for a patient motivated to try it.
Smoking cessation
Directly relevant, not generic advice nicotine is directly vasoconstrictive and both triggers and worsens Raynaud's attacks[1] — frame cessation counselling around this specific, immediate mechanism rather than only long-term cardiovascular risk, since a patient may respond better to "this is actively causing your finger attacks" than to generic anti-smoking messaging. Offer pharmacotherapy and connect the patient with cessation supports rather than a simple instruction to stop.
Trigger-drug avoidance, where feasible
Cross-reference the drug-culprit table (see Drug Tables) at every visit — avoiding a genuinely avoidable vasoconstrictive medication (an OTC decongestant during cold-and-flu season, for example) is a simple, high-value, and often overlooked non-pharmacologic intervention.[5] For a prescription medication, this needs prescriber collaboration rather than unilateral patient action (see Choose Initial Treatment).
General measures
- Regular aerobic exercise supports overall vascular health and is not contraindicated by Raynaud's phenomenon itself, though outdoor exercise in cold weather needs the same layering and warming precautions.
- Maintain adequate hydration.
- Protect the digits from even minor trauma in secondary disease, where a small cut or hangnail can become a genuine, slow-healing ulcer rather than a trivial injury.
- A symptom diary (frequency, duration, severity, and any identified trigger) is genuinely useful both for the patient's own trigger-avoidance and for objectively judging treatment response at follow-up.
Special Populations
Pregnancy and breastfeeding — including Raynaud's phenomenon of the nipple
Raynaud's phenomenon of the nipple is a real, genuinely under-recognized cause of significant nipple pain during breastfeeding, distinct from the far more commonly assumed causes (poor latch, candidal infection, or bacterial mastitis). It presents as episodic nipple blanching — classically triggered by the cold immediately after a feed as the nipple is exposed to air, or by the mechanical stimulus of latch itself — followed by cyanosis and/or a painful red, throbbing reperfusion phase, and is easily misattributed to thrush if this specific trigger pattern is not asked about directly.[1] Confirm latch technique first, keep the nipple warm and dry immediately after feeds, and avoid caffeine and nicotine; if pharmacotherapy is genuinely needed, oral nifedipine (extended-release) is the best-studied option and is considered compatible with breastfeeding.[8] For pregnancy generally, dihydropyridine calcium channel blockers, with nifedipine again the best-established, are considered a reasonable choice when pharmacotherapy is needed; avoid losartan, which is contraindicated in pregnancy, and reassess any drug-culprit medication in the context of pregnancy-specific safety, not only Raynaud's-specific risk.
Pediatrics
Most children presenting with Raynaud's phenomenon have primary disease with a genuinely benign course, but a positive ANA, a connective-tissue-disease-associated autoantibody, or abnormal nailfold capillary changes should prompt referral to pediatric rheumatology and closer follow-up, since these findings identify a real subset at risk for an evolving systemic disease.[6] Reassurance and non-pharmacologic measures are the mainstay for straightforward pediatric primary disease; pharmacotherapy trial evidence in children is limited, and a calcium channel blocker trial, when genuinely needed, should be undertaken with the same low-dose, gradually titrated approach as in adults.[6]
Older adults
New Raynaud's phenomenon presenting for the first time in an older adult is more likely to be secondary — screen actively for atherosclerotic peripheral arterial disease and for a drug-induced cause, which is disproportionately likely in this group given typical polypharmacy (a beta-blocker for a cardiac indication is a common, easily overlooked culprit).[5] Calcium channel blockers are generally well tolerated but watch more closely for hypotension and peripheral edema.
Systemic sclerosis (scleroderma) and other connective tissue disease
This is the population carrying the great majority of the genuine digital-ulceration and critical-ischemia risk this chapter is centred on preventing, and the population the escalation ladder in Choose Initial Treatment and the Clinical Decision Algorithm is largely built around.[8][4] Close co-management with rheumatology (and vascular surgery once ulceration or critical ischemia develops) is appropriate rather than managing this group purely in primary care or community pharmacy. Digital ulcer wound care, prompt recognition of superimposed infection, and avoiding premature or overly pessimistic conversations about amputation before a wound has had adequate time and specialist assessment are all genuinely relevant here, echoing the same demarcation-before-amputation principle covered in more depth in this platform's separate Frostbite chapter.
Occupational hand-arm vibration syndrome
Where vibrating-tool exposure is a contributing factor, workplace modification (anti-vibration equipment, tool substitution, scheduled breaks, and glove use) is a genuine and often underused intervention; consider whether an occupational health or workers' compensation referral is appropriate.
Renal and hepatic impairment
Dihydropyridine calcium channel blockers require little renal dose adjustment but should be used cautiously in significant hepatic impairment, where clearance is reduced. Sildenafil and tadalafil both require dose adjustment in significant renal or hepatic impairment — confirm the current recommendation against each drug's own Drug Database entry before use. Losartan requires caution in significant renal impairment given its effect on potassium and renal hemodynamics.
Monitoring & Follow-Up
Reassess attack frequency, severity, and duration at every follow-up, ideally against the patient's own symptom diary rather than relying on recall alone — this is what actually judges whether a change (non-pharmacologic, medication adjustment, or a new drug) is working.[1]
- Examine the digits specifically for new pitting, ulceration, or any sign of tissue breakdown at every visit in a patient with known or suspected secondary disease — this is the single highest-yield follow-up action in this chapter for the population that actually loses tissue.
- Check blood pressure and heart rate, and ask about peripheral edema, at each calcium channel blocker dose titration.
- Reassess the primary-versus-secondary classification over time, not only at the initial visit — secondary features (new ulceration, new autoantibody positivity, evolving skin changes) can emerge later in a patient initially and correctly classified as primary at first presentation.[3]
- Reconcile the full medication list at every visit for a newly started or dose-increased culprit drug, not only at the original diagnosis.[5]
- Reassess smoking status and reinforce cessation support at every visit where relevant.
- For a patient on combination pharmacotherapy (calcium channel blocker plus a PDE5 inhibitor and/or topical nitrate), confirm the added agent is genuinely contributing before continuing it indefinitely — deprescribe an agent that has not produced a meaningful benefit after an adequate trial.
- For secondary disease under specialist co-management, confirm the patient is actually attending rheumatology/vascular follow-up rather than assuming this is happening.
Common Errors to Avoid
- Assuming every case of Raynaud's phenomenon is benign primary disease without actively screening for the secondary-disease red flags.
- Insisting on a textbook-perfect white-blue-red triphasic history before accepting the diagnosis — a biphasic or monophasic colour change is still genuine Raynaud's phenomenon.
- Missing a "hidden" culprit drug — ophthalmic timolol, an OTC decongestant, or an ADHD stimulant are all real, common, and easy to overlook if the medication review is limited to obvious oral cardiovascular drugs.
- Stopping a needed beta-blocker (for example, one started after myocardial infarction) unilaterally rather than discussing dose reduction, substitution, or a supervised taper with the prescriber.
- Prescribing or recommending short-acting immediate-release nifedipine instead of an extended-release formulation, risking reflex tachycardia and hypotension without added efficacy.
- Advising only local hand warming while overlooking the genuine contribution of whole-body/core cold exposure to triggering an attack.
- Confusing Raynaud's phenomenon with erythromelalgia — the two are pathophysiologic opposites (vasospasm versus vasodilation), and a vasodilating treatment appropriate for one can worsen the other.
- Delaying rheumatology referral in a patient with new digital ulceration or pitting while continuing to manage it as routine primary-disease follow-up.
- Attributing nipple pain during breastfeeding to thrush or poor latch without asking about the specific cold-triggered blanching pattern of Raynaud's phenomenon of the nipple.
- Starting losartan in a woman of childbearing age without confirming pregnancy status or plans first.
- Treating "cold hands" or diffuse mottling without a well-demarcated colour change as Raynaud's phenomenon.
- Not reassessing the primary-versus-secondary classification over time, assuming an initial benign classification holds indefinitely.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Beta-Blockers
The single most common secondary-Raynaud's-associated drug class — non-selective agents carry the strongest association, but cardioselective agents and even ophthalmic (eye-drop) formulations are genuinely capable of causing or worsening attacks through systemic absorption.[5]
| Drug | Typical dosing (for its own indication) | Raynaud's-relevant effect | Drug interactions | Management comment |
|---|---|---|---|---|
| Propranolol | Adults: 10-80 mg PO in divided doses daily (dose is highly indication-dependent) | Peripheral vasoconstriction from unopposed alpha-adrenergic tone once beta-2-mediated vasodilation is blocked — the strongest beta-blocker association | Additive vasoconstriction with other culprit drugs in this table | Non-selective agents carry the highest risk in this class; discuss a cardioselective substitute or dose reduction with the prescriber where the indication allows. |
| Atenolol | Adults: 25-100 mg PO once daily | Lower but real risk than a non-selective agent, since beta-1 selectivity is only relative, not absolute | Additive vasoconstriction with other culprit drugs in this table | A common substitution target when a cardioselective agent is preferred, though it does not eliminate the risk entirely. |
| Timolol maleate (ophthalmic) | Adults: 1 drop of 0.25% or 0.5% ophthalmic solution to the affected eye(s) once or twice daily | Systemic absorption through the nasolacrimal duct is genuinely sufficient to precipitate or worsen Raynaud's phenomenon despite being "just eye drops" | Additive vasoconstriction with an oral beta-blocker or another culprit drug | Easy to miss on medication review unless glaucoma drops are specifically asked about; punctal occlusion after instillation reduces systemic absorption if the drug cannot be changed. |
Ergot Alkaloids and Triptans
Both classes act on serotonergic and/or alpha-adrenergic receptors to produce direct vasoconstriction — genuinely useful for aborting a migraine, but the same mechanism can precipitate or worsen Raynaud's phenomenon.
| Drug | Typical dosing (for its own indication) | Raynaud's-relevant effect | Drug interactions | Management comment |
|---|---|---|---|---|
| Dihydroergotamine | Adults: 0.5 mg per nasal spray dose, per product labelling | Direct arterial vasoconstriction via alpha-adrenergic and serotonergic receptor agonism; case reports of severe digital ischemia | Contraindicated with a triptan or another vasoconstrictive migraine agent within 24 hours | Reserve for a patient without a Raynaud's phenomenon history where possible; stop at the first sign of digital ischemia. |
| Sumatriptan | Adults: 50-100 mg PO at onset, may repeat once after 2 hours, maximum 200 mg/day | 5-HT1 receptor agonism causes vasoconstriction beyond the intended cranial vasculature | Avoid combining with an ergot alkaloid or another triptan within 24 hours | A patient with known Raynaud's phenomenon who needs migraine abortive therapy may tolerate a non-vasoconstrictive alternative (for example, an NSAID or a CGRP-targeted agent) better. |
| Rizatriptan | Adults: 5-10 mg PO at onset, may repeat after 2 hours, maximum 30 mg/day | Same vasoconstrictive mechanism as other triptans | Avoid combining with an ergot alkaloid or another triptan within 24 hours | Consider a non-vasoconstrictive migraine strategy first-line in a patient with known Raynaud's phenomenon. |
Chemotherapy Agents
Well documented specifically with combination regimens for germ-cell (testicular) cancer — bleomycin and cisplatin carry the strongest individual association, and the combination of bleomycin with vinblastine carries a materially higher risk than bleomycin with etoposide. Onset is typically 3-6 months after starting therapy and can persist for years after treatment ends.[10]
| Drug | Typical dosing (for its own indication) | Raynaud's-relevant effect | Drug interactions | Management comment |
|---|---|---|---|---|
| Bleomycin | Regimen-dependent: Per oncology protocol | Direct endothelial toxicity and vasospasm; risk rises with cumulative dose | Combination with vinblastine carries higher risk than with etoposide | Per oncology protocol (for example, a bleomycin-containing germ-cell-tumour regimen) — dosing is regimen-specific, not community-titrated. |
| Cisplatin | Regimen-dependent: Per oncology protocol | Vascular endothelial toxicity contributing to vasospasm, often in combination with the other agents in this class | Additive vascular toxicity with bleomycin and vinblastine in combination regimens | Per oncology protocol — dosing is regimen-specific, not community-titrated. |
| Vinblastine | Regimen-dependent: Per oncology protocol | Contributes to the combination-regimen risk, particularly alongside bleomycin | Additive vascular toxicity with bleomycin and cisplatin in combination regimens | Per oncology protocol — dosing is regimen-specific, not community-titrated. |
Clonidine and Other Centrally Acting Alpha-2 Agonists
A well-recognized, if under-appreciated, cause — the same alpha-2-agonist mechanism that lowers blood pressure centrally also enhances cold-amplified peripheral alpha-2c-receptor-mediated vasoconstriction.
| Drug | Typical dosing (for its own indication) | Raynaud's-relevant effect | Drug interactions | Management comment |
|---|---|---|---|---|
| Clonidine | Adults: 0.1-0.3 mg PO twice daily (dose is highly indication-dependent) | Peripheral alpha-2c-receptor-mediated vasoconstriction, amplified by cold | Additive vasoconstriction with other culprit drugs in this table | Discuss an alternative antihypertensive or a supervised taper with the prescriber where the indication allows — do not stop an antihypertensive agent like this abruptly. |
Decongestants and Other Sympathomimetics
Direct alpha-adrenergic agonists — genuinely common, easy-to-overlook culprits precisely because they are over-the-counter and often taken only intermittently for a cold or allergy symptoms rather than as a scheduled medication.
| Drug | Typical dosing (for its own indication) | Raynaud's-relevant effect | Drug interactions | Management comment |
|---|---|---|---|---|
| Pseudoephedrine | Adults: 60 mg PO every 4-6 hours PRN (immediate-release), or 120 mg every 12 hours/240 mg once daily (extended-release) | Direct alpha-adrenergic-agonist-mediated vasoconstriction | Additive vasoconstriction with any other culprit drug in this table, including an ADHD stimulant or a decongestant nasal spray | Ask specifically about OTC cold/allergy product use — this is very easy for a patient to omit from a medication list entirely. |
ADHD Stimulants
Both methylphenidate- and amphetamine-class stimulants are recognized causes of new or worsened Raynaud's phenomenon, working through peripheral catecholamine release and reuptake inhibition; amphetamine-class agents (which both release and inhibit reuptake of catecholamines) appear to carry a higher reported risk than methylphenidate-class agents (reuptake inhibition alone).[11]
| Drug | Typical dosing (for its own indication) | Raynaud's-relevant effect | Drug interactions | Management comment |
|---|---|---|---|---|
| Methylphenidate | Adults/children: 18-54 mg PO once daily (extended-release), titrated per response | Catecholamine-reuptake-inhibition-mediated peripheral vasoconstriction | Additive vasoconstriction with a decongestant or another culprit drug in this table | Symptoms are often, though not always, dose-related and may improve with a dose reduction rather than requiring discontinuation — discuss with the prescriber. |
| Mixed salts amphetamine | Adults/children: 5-30 mg PO once or twice daily, titrated per response | Both catecholamine release and reuptake inhibition — a more pronounced vasoconstrictive effect than methylphenidate-class agents in reported cases | Additive vasoconstriction with a decongestant or another culprit drug in this table | Consider a methylphenidate-class alternative if ADHD therapy cannot be interrupted and Raynaud's phenomenon is significant. |
Interferons
Recognized specifically with interferon-alfa (oncology, chronic viral hepatitis) and interferon-beta (multiple sclerosis) therapy, with case reports ranging from mild vasospasm to digital ischemia and, rarely, tissue loss; onset can be weeks to years after starting therapy.
| Drug | Typical dosing (for its own indication) | Raynaud's-relevant effect | Drug interactions | Management comment |
|---|---|---|---|---|
| Interferon beta-1a | MS therapy: Per product-specific regimen | Vascular endothelial toxicity contributing to vasospasm; reported specifically in multiple sclerosis therapy | Additive vascular toxicity with any other culprit drug in this table | Per product-specific multiple sclerosis dosing regimen — dose and frequency vary substantially between specific interferon-beta products. |
| Peginterferon alfa-2a | Regimen-dependent: Per product-specific regimen | Vascular endothelial toxicity contributing to vasospasm; reported specifically in oncology and chronic viral hepatitis therapy | Additive vascular toxicity with any other culprit drug in this table | Per product-specific oncology/hepatitis regimen — dosing is regimen- and indication-specific. |
References
- Raynaud Phenomenon — New England Journal of Medicine (Wigley FM, Flavahan NA). N Engl J Med 2016;375(6):556-565
- International consensus criteria for the diagnosis of Raynaud's phenomenon — Journal of Autoimmunity (Maverakis E, Patel F, Kronenberg DG, et al.). J Autoimmun 2014;48-49:60-65
- Raynaud's phenomenon: a proposal for classification — Clinical and Experimental Rheumatology (LeRoy EC, Medsger TA Jr). Clin Exp Rheumatol 1992;10(5):485-488
- Systemic sclerosis — CMAJ (Osman M, Saed Aldien A, Netchiporouk E). CMAJ 2026;198(14):E553
- Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers — British Journal of Clinical Pharmacology (Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M). Br J Clin Pharmacol 2016;82(1):6-16
- Raynaud phenomenon in children — Canadian Family Physician (Goldman RD). Can Fam Physician 2019;65(4):264-265
- Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis — Autoimmunity Reviews (Smith V, Herrick AL, Ingegnoli F, et al.). Autoimmun Rev 2020;19(3):102458
- EULAR recommendations for the treatment of systemic sclerosis: 2023 update — Annals of the Rheumatic Diseases (Del Galdo F, Lescoat A, Conaghan PG, et al.). Ann Rheum Dis 2025;84(1):29-40
- On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials — Annals of Internal Medicine (Roustit M, Giai J, Gaget O, et al.). Ann Intern Med 2018;169(10):694-703
- Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold — Journal of Clinical Oncology (Hansen SW, Olsen N). J Clin Oncol 1989;7(7):940-942
- Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: a scoping review — Seminars in Arthritis and Rheumatism (Umair HM, Sandler RD, Alunno A, Matucci-Cerinic M, Hughes M). Semin Arthritis Rheum 2021;51(6):1200-1204
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.